On June 13, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of repotrectinib (Augtyro™) to treat patients with advanced NTRK-positive solid tumors who have either had their disease recur or who don’t have alternative treatment options. This treatment is part of a growing trend of tissue-agnostic drugs—treatments that are prescribed based on the biomarkers found in the tumor rather than the organ where the cancer originated.   It is available to patients through the FDA’s accelerated approval process, which hurries exciting treatments to patients who need them

Read time: 2 minutes Integrative oncology adds holistic approaches—such as acupuncture, nutrition, exercise, and mindfulness—into a treatment plan. Research shows these interventions can have a tremendous impact on people going through lung cancer treatment and their quality of life. Unfortunately, they are also topics riddled with myths and falsehoods. LUNGevity spoke to an expert to help sort out the facts from the fiction. In the webinar below, Gabriel Lopez, MD, medical director of the Integrative Medicine Center at MD Anderson Cancer Center, explains how integrative medicine can be safely

This March, LUNGevity Foundation partnered with CURE for their “Speaking Out” video series, inviting Amy Moore, PhD, vice president of global engagement and patient partnerships at LUNGevity Foundation, to discuss recent chemotherapy shortages. During the interview, Dr. Moore addressed the critical issues posed by the chemotherapy shortage, offering valuable insights into its origins, impact on people with lung cancer, available alternatives, and ongoing efforts to address disparities. Her expertise provides essential understanding for anyone interested in the complexities of lung cancer

On April 5, 2024, the US Food and Drug Administration (FDA) announced the accelerated approval of fam-trastuzumab deruxtecan-nxki (Enhertu®) to treat patients with unresectable or metastatic HER2-positive solid tumors. This treatment is part of a growing trend of tissue-agnostic drugs -- treatments that are prescribed based on the biomarkers found in the tumor rather than the organ where the cancer originated. It is available to patients through the FDA’s accelerated approval process, which hurries exciting treatments to patients who need them. Accelerated approvals can be controversial

In the past five years, the lung cancer community has seen an astonishing number of new treatments. As our understanding of lung cancer has deepened, the older treatment approaches have also become more effective and efficient. These options are fantastic steps toward improving the overall survival and quality of life for people living with lung cancer, but it can be difficult for patients and caregivers to keep track of the new drug treatments and scientific advancements. Each year, LUNGevity offers a free virtual conference, the International Lung Cancer Survivorship Conference, or ILCSC, to

Asking your doctor and medical team questions about clinical trials is a helpful way to decide if they are a good fit for you. You may already have some in mind, but a few basic questions to ask and get answered before making a decision are: Do you know of any clinical trials for my type and stage of lung cancer? What are the benefits and risks of this clinical trial? What are the eligibility guidelines? How long does the study last? Will you still be in charge of my care? What are the costs, and what will my insurance cover? Are there other people I can talk to about this study, or a place I

The four phases of lung cancer clinical trials each serve a different and important purpose. From testing the safety of a new treatment to its effectiveness and long-term outcomes, this short video explains how researchers use clinical trials for new lung cancer treatments. Phases of a Clinical Trial: 1. Safety of the new treatment 2. Does the cancer respond to the treatment 3. Is this new treatment better than the current options 4. Studies the long-term benefits and side effects

On November 15, 2023, the US Food and Drug Administration (FDA) announced the approval of repotrectinib to treat patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC). Repotrectinib is part of a class of drugs called tyrosine kinase inhibitors, or TKIs, which have been beneficial for many patients with oncogene-driven lung cancers. TKIs are a type of therapy that specifically targets changes in genes that are known to promote tumor growth. Repotrectinib is the third TKI drug for ROS1-positive NSCLC but is the first to be used for patients who either have

Lung cancer clinical trials are carefully designed research studies to evaluate and learn more about new drugs and treatments. They give people the ability to participate in lung cancer research and access to new treatments that otherwise may not be available to them, all under the close supervision of medical experts.

The International Lung Cancer Survivorship Conference (ILCSC) is a free virtual educational conference for people with lung cancer, caregivers, and advocates. The 2023 conference was held September 22-23. The recorded sessions from this conference are available to registered participants through December 21, 2023, at www.lungevity.org/ilcsc. If you did not register for the conference but would like to view the recordings, you may still register for free access. The recordings are available until December 21. The recordings provide opportunities for attendees to hear from world-renowned